Biotech Values

[DewDiligence]

> Athenagen – I can't imagine how the application of an anti-angiogenesis compound to the (vascularized) orbital socket outside the eye could target the retina (on the other side of the sclera) yet not the systemic circulation.<

Yet this is what the company claims to have accomplished in animals. Without knowing any of the details, I imagined that this feat was achieved because the compound rapidly degrades in general circulation. A drug with a similar property that comes to mind—although it is from a completely different class and is being tested in an unrelated indication—is NUVO’s Alfimeprase.